sur Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health Reports Strong Q3 2024 Financial Performance
Jaguar Health, Inc. announced a notable increase in third-quarter 2024 financials with net revenues reaching approximately $3.1 million. This marks a 14% increase from Q2 2024 and an 11% rise from Q3 2023. The company's revenue growth is attributed to both prescription and non-prescription products, as well as license revenue.
Significantly, Jaguar achieved promising results in its phase 3 OnTarget trial for crofelemer, aimed at cancer supportive care in breast cancer patients. These findings will be showcased at the San Antonio Breast Cancer Symposium in December 2024. October also saw the commercial launch of Gelclair®, further emphasizing Jaguar's focus on cancer supportive care.
The company is setting the stage for continued innovation, with two Phase 2 trials and multiple proof-of-concept studies of crofelemer slated for Q4 2024, targeting rare diseases such as microvillus inclusion disease (MVID) and short bowel syndrome (SBS).
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.